secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001193125-22-280241
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 2.01, 1.01, 5.07, 3.02, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silverback Therapeutics merges with ARS Pharma; renamed ARS Pharmaceuticals, new board and focus on neffy
--------------------------------------------------------------------------------

- Merger completed Nov 8, 2022; ARS Pharma becomes wholly owned subsidiary of re-named ARS Pharmaceuticals, Inc.
- ARS Pharma equityholders own ~62% and prior Silverback equityholders ~38% on a fully diluted basis post-merger.
- New board includes eight ARS Pharma designees; executives: Richard Lowenthal (CEO), Kathleen Scott (CFO), Sarina Tanimoto (CMO), Eric Karas (CCO), Justin Chakma (CBO/Secretary).
- Company now focusing on neffy (intranasal epinephrine) for Type I allergic reactions and anaphylaxis.
- Stock symbol changes from SBTX to SPRY, effective Nov 9, 2022, on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/0001193125-22-280241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522280241/d388226d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-280241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer